Predisposition to invasive fungal disease due to CARD9 deficiency: A Patient Guide
At a Glance
CARD9 deficiency is an inherited immune-system disorder that can cause serious, slow-developing fungal infections in the skin, bones, brain, or spinal cord. Genetic testing confirms the diagnosis, and prolonged antifungal treatment with specialist monitoring may reduce relapse risk.
This guide provides educational information; your immunologist and infectious-disease clinician will determine your specific treatment, prophylaxis, imaging, and laboratory schedules. It is highly recommended to keep a written emergency plan and medication list with you at all times.
Predisposition to invasive fungal disease due to CARD9 deficiency is a rare, inherited condition that creates a highly specific vulnerability or “blind spot” in the immune system. While most people with this condition are otherwise healthy and effectively fight off common viruses and bacteria, their bodies struggle to recognize and respond to certain types of fungi [1]. This is because the CARD9 protein acts as a critical messenger that tells the immune system to launch an attack when a fungus is detected; without it, the alarm may fail to sound, and the body can fail to recruit the necessary defenses [2].
This specific immune defect can lead to deep, invasive fungal infections that move beyond the surface of the skin and into vital organs like the brain, spinal cord, or bones [1]. These are not typical superficial issues like athlete’s foot or a simple yeast infection; they are severe, potentially life-threatening illnesses such as CNS candidiasis (fungal infection of the brain), deep dermatophytosis (deep skin and bone infection), or phaeohyphomycosis (infections caused by certain molds) [3]. Because the body’s natural warning systems can be muted, these infections can develop slowly and may go unnoticed until they have caused significant damage [4].
Diagnosing CARD9 deficiency is often a challenge because a patient’s routine immune blood work—such as white blood cell counts and antibody levels—typically looks completely normal [5]. The immune system has the “soldiers” it needs, but they simply aren’t receiving their orders to fight fungi. Consequently, a definitive diagnosis requires specialized genetic testing to identify mutations in both copies of the CARD9 gene [6]. This genetic root also means the condition is autosomal recessive, meaning it is passed down through families. It is common for symptoms to first appear in childhood, but the condition can also remain “hidden” until late adulthood, with first infections reported in people as old as 91 [3].
Living with this condition requires a long-term, proactive strategy focused on both treatment and prevention. Because the body’s defense pathways for clearing these fungi are impaired, patients often require exceptionally long courses of powerful antifungal medications—sometimes lasting a year or more—to ensure an infection is fully controlled [7]. Even after an infection seems to have cleared, the risk of it returning can be high. Depending on the infection site, organism, and response, this sometimes necessitates long-term “suppressive” therapy to prevent a relapse [1].
Because of the inherited nature of the disease, it is also standard practice to recommend genetic counseling and cascade testing for a patient’s siblings. Siblings may carry the same genetic profile and be at risk for future infections even if they currently feel perfectly healthy [6]. Although the diagnosis requires lifelong vigilance, an accurate understanding of this specific immune defect allows for targeted care that can effectively manage the risk and protect long-term health [8].
In this guide
6 chapters
Understanding Your Diagnosis: CARD9 Deficiency
Learn what CARD9 deficiency means, how it affects antifungal immunity, which fungal infections can occur, how it is inherited, and why relatives may need testing.
Symptoms and Warning Signs
Learn the warning signs of invasive fungal disease in CARD9 deficiency, including deep skin lesions, headache, vision changes, and emergency symptoms.
Getting an Accurate Diagnosis: Labs and Genetics
Learn how CARD9 deficiency is diagnosed when routine immune tests are normal, including genetic testing, functional assays, and screening for at-risk relatives.
Treatment Options and How Doctors Choose Among Them
Learn how CARD9 deficiency affects invasive fungal treatment, including induction, monitoring, surgery, and long-term relapse prevention under specialist care.
Advanced Therapies: Cytokines and Stem Cell Transplant
Learn when cytokines or stem cell transplant may be considered for CARD9 deficiency, including potential benefits, serious risks, and why expert care matters.
Long-Term Monitoring and Survivorship
Learn how CARD9 deficiency affects long-term monitoring and survivorship, including relapse signs, organ follow-up, antifungal safety, and family testing.
Common questions in this guide
What does CARD9 deficiency mean for my risk of fungal infections?
Which fungal infections are linked to CARD9 deficiency?
Can standard immune blood tests miss CARD9 deficiency?
Is CARD9 deficiency inherited, and should my siblings be tested?
How long might antifungal treatment last with CARD9 deficiency?
What ongoing monitoring is needed for CARD9 deficiency?
Get notified when new evidence is published on Predisposition to invasive fungal disease due to CARD9 deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (8)
- 1
Inherited CARD9 Deficiency: Invasive Disease Caused by Ascomycete Fungi in Previously Healthy Children and Adults.
Corvilain E, Casanova JL, Puel A
Journal of clinical immunology 2018; (38(6)):656-693 doi:10.1007/s10875-018-0539-2.
PMID: 30136218 - 2
Mechanistic Insights into the Role of C-Type Lectin Receptor/CARD9 Signaling in Human Antifungal Immunity.
Drummond RA, Lionakis MS
Frontiers in cellular and infection microbiology 2016; (6()):39 doi:10.3389/fcimb.2016.00039.
PMID: 27092298 - 3
Clinical features of patients with fungal infections caused by CARD9 deficiency: a literature review of case reports.
Tang C, Liu Y, Long J, Lv X
Frontiers in cellular and infection microbiology 2025; (15()):1615929 doi:10.3389/fcimb.2025.1615929.
PMID: 40740345 - 4
[CARD9 Mutation in a Patient with Candida albicans Meningoencephalitis; A Case Report].
Kuruoğlu T, Çelik M, Çelmeli F, Tanyel E
Mikrobiyoloji bulteni 2021; (55(4)):656-664 doi:10.5578/mb.20219717.
PMID: 34666665 - 5
Extrapulmonary Aspergillus infection in patients with CARD9 deficiency.
Rieber N, Gazendam RP, Freeman AF, et al.
JCI insight 2016; (1(17)):e89890.
PMID: 27777981 - 6
Inherited CARD9 Deficiency in a Child with Invasive Disease Due to Exophiala dermatitidis and Two Older but Asymptomatic Siblings.
Imanaka Y, Taniguchi M, Doi T, et al.
Journal of clinical immunology 2021; (41(5)):975-986 doi:10.1007/s10875-021-00988-7.
PMID: 33558980 - 7
Chronic Candida albicans Meningitis in a 4-Year-Old Girl with a Homozygous Mutation in the CARD9 Gene (Q295X).
Herbst M, Gazendam R, Reimnitz D, et al.
The Pediatric infectious disease journal 2015; (34(9)):999-1002 doi:10.1097/INF.0000000000000736.
PMID: 25933095 - 8
Successful Allogenic Stem Cell Transplantation in Patients with Inherited CARD9 Deficiency.
Queiroz-Telles F, Mercier T, Maertens J, et al.
Journal of clinical immunology 2019; (39(5)):462-469 doi:10.1007/s10875-019-00662-z.
PMID: 31222666
This page is for informational purposes only and does not constitute medical advice. Your immunologist and infectious-disease clinician should tailor genetic testing, antifungal treatment, prophylaxis, and monitoring to your situation.